Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis to Hold On to Its 33 Percent Stake in Roche – For Now

Basel, Switzerland-based Novartis has decided not to sell its $14 billion stake in Swiss rival Roche.

Read More »

Enabling Digital Transformation With a Seamless and Secure Digital Experience

Hear from featured guest Merritt Maxim, Principal Analyst at Forrester Research, about the 6 key customer-centric objectives that every organization should be tackling.

Read More »

Spark gene therapy improves vision, at least in short term: FDA

Spark Therapeutics Inc.’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.

Read More »

Flexion’s knee pain drug gets FDA nod

Flexion Therapeutics Inc.’s injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer’s shares soaring to a record high in regular trading.

Read More »

Acerta Pharmaceuticals Falsified Early Data on Cancer Compound, Now in Clinical Trials

Acerta Pharmaceuticals is being forced to retract claims of a therapeutic benefit of acalabrutinib in a mouse model of pancreatic cancer that was published in three medical journals two years ago due to falsified data.

Read More »

J&J unit exits insulin pump business

Johnson & Johnson’s diabetes care unit will shut down its business in the United States and Canada amid increased competition and after failing to find a buyer.

Read More »

Acadia Scraps Phase II Alzheimer’s Trial, Gets Breakthrough Tag for Dementia-Related Drug

After posting mixed results for its pimavanserin trial in December 2016, Acadia Pharmaceuticals is broadening its research focus from Alzheimer’s disease psychosis to the treatment of hallucinations and delusions associated with dementia-related psychosis.

Read More »

FDA approves Mylan’s Copaxone copy

Mylan received long-awaited U.S. approval for its generic version of rival Teva’s blockbuster multiple sclerosis treatment Copaxone.

Read More »

Sarepta Jumps Despite DMD Safety Issues in FDA Database

Shares of Sarepta Therapeutics recovered from a dip of about 8 percent as investors seem to have rallied behind the company’s Duchenne muscular dystrophy (DMD) drug Exondys 51.

Read More »

Ablynx scores big hit with blood disease drug

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom